Roivant Sciences (FRA:87S) FFO per Share


FRA:87S Roivant Sciences Ltd FRA:87S
51 GF Score
Price €31.09
GF Value €9.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences FFO per Share?

FFO per Share only applies to REITs.

FRA:87S
51GF Score
Roivant Sciences Ltd FRA:87S
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €31.09 is trading 217.2% above its estimated GF Value™ of €9.80. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • FFO per Share:
  • GF Value™: €9.80 vs. price of €31.09 (217.2% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for FRA:87S

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.09
Price
€9.80
GF Value